Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:33:28.289Z.
Calculation as of: 2026-10-06T20:33:28.289Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aebbac3c8f5cd71f6a0736116a7e77570b12e82b9576f853dd4f644618eebaf7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
vTv Therapeutics Inc.
Market Cap
$78.59M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| vTv Therapeutics Inc. (VTVT) | $78.59M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
